Literature DB >> 7103772

Amyloid-associated muscle pseudohypertrophy.

S P Ringel, H N Claman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7103772     DOI： 10.1001/archneur.1982.00510190031009

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


× No keyword cloud information.
  7 in total

1.  In vitro myotrophic effect of serum kappa chain immunoglobulins from a patient with kappa light chain myeloma and muscular hypertrophy.

Authors:  C Delaporte; B Varet; M Fardeau; D Nochy; A Ract
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

2.  Early sarcolemmal dysfunction in skeletal muscle amyloidosis.

Authors:  C Doriguzzi; T Mongini; W Troni; G Monga
Journal:  J Neurol       Date:  1987-01       Impact factor: 4.849

3.  Proximal weakness of the extremities as main feature of amyloid myopathy.

Authors:  F G Jennekens; J H Wokke
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-10       Impact factor: 10.154

4.  Myopathy in primary systemic amyloidosis.

Authors:  M A Gertz; R A Kyle
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

5.  Amyloid myopathy presenting with respiratory failure.

Authors:  J Ashe; C O Borel; G Hart; R L Humphrey; D A Derrick; R W Kuncl
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-02       Impact factor: 10.154

6.  MRI evaluation of amyloid myopathy.

Authors:  J P Metzler; J L Fleckenstein; C L White; R G Haller; E P Frenkel; R G Greenlee
Journal:  Skeletal Radiol       Date:  1992       Impact factor: 2.199

7.  Chronic myopathy due to immunoglobulin light chain amyloidosis.

Authors:  Irini Manoli; Justin Y Kwan; Qian Wang; Elisabeth J Rushing; Maria Tsokos; Andrew E Arai; Warner M Burch; Angela Dispenzieri; Alexandra C McPherron; William A Gahl
Journal:  Mol Genet Metab       Date:  2013-02-04       Impact factor: 4.797
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.